lassa
fever
acut
viral
haemorrhag
ill
caus
lassa
viru
lasv
endem
throughout
much
west
africa
viru
primarili
circul
mastomi
natalensi
reservoir
transmit
human
contact
infecti
rodent
secret
humantohuman
transmiss
document
well
except
dengu
fever
lasv
highest
human
impact
haemorrhag
fever
viru
ongo
outbreak
nigeria
result
unpreced
mortal
consequ
world
health
organ
list
lasv
high
prioriti
pathogen
develop
treatment
prophylact
current
licens
vaccin
protect
lasv
infect
although
numer
candid
demonstr
efficaci
anim
model
date
singl
candid
advanc
clinic
trial
lassa
fever
vaccin
develop
effort
hinder
high
cost
biocontain
requir
absenc
establish
correl
protect
uncertainti
regard
extent
anim
model
predict
vaccin
efficaci
human
review
briefli
discuss
epidemiolog
biolog
lasv
infect
highlight
recent
progress
vaccin
develop
lassa
viru
lasv
first
identifi
death
two
missionari
nurs
nigeria
acut
viral
haemorrhag
fever
annual
incid
lasv
infect
rang
case
associ
mortal
death
per
year
lassa
fever
endem
sever
west
african
countri
sierraleon
liberia
guinea
nigeria
heavili
affect
howev
lasv
infect
also
detect
throughout
divoir
togo
benin
ghana
central
african
republ
democrat
republ
congo
seneg
southern
mali
nonspecif
febril
ill
high
proport
asymptomat
case
lasv
infect
often
unreport
misdiagnos
preclud
accur
determin
true
burden
past
three
year
document
case
lassa
fever
steadili
rise
nigeria
garner
intern
attent
laboratoryconfirm
case
surg
unsurprisingli
part
effort
establish
global
strategi
improv
epidem
prepared
respons
world
health
organ
list
lasv
prioriti
pathogen
need
acceler
research
develop
new
vaccin
therapeut
diagnost
review
briefli
summaris
lassa
fever
virolog
epidemiolog
immunobiolog
discuss
promis
vaccin
candid
select
expedit
develop
virolog
epidemiolog
patholog
viral
genom
structur
lasv
belong
arenavirida
famili
envelop
singlestrand
rna
viru
biseg
ambisens
genom
viru
spheric
shape
diamet
rang
nm
envelop
surfac
smooth
tshape
glycoprotein
spike
enclos
genom
contain
helic
nucleocapsid
nm
length
viral
genom
consist
larg
l
small
rna
fragment
kb
size
respect
l
fragment
encod
rnadepend
rna
polymeras
small
zincbind
z
protein
meanwhil
fragment
encod
viral
glycoprotein
precursor
gpc
nucleoprotein
np
glycoprotein
gp
spike
complex
drive
host
cell
entri
matur
form
gp
trimer
heterodim
contain
receptorbind
subunit
transmembran
fusionmedi
subunit
gpc
also
encod
stabl
signal
peptid
ssp
aid
polyprotein
process
regul
ph
infect
provis
chaperon
function
gp
matur
focu
recent
lasv
antivir
vaccin
research
structur
analys
gp
indic
primari
target
neutralis
antibodi
bind
howev
role
npspecif
cell
control
acut
infect
mediat
heterosubtyp
immun
anim
model
lassa
fever
patient
offer
justif
inclus
np
lasv
vaccin
lasv
zoonot
pathogen
circul
rodent
reservoir
sever
decad
natal
multimamm
rat
mastomi
natalensi
assum
host
lasv
howev
recent
evid
indic
lasv
circul
rodent
speci
fact
isol
lasv
african
wood
mous
hylomyscu
pamfi
nigeria
guinea
multimamm
mous
mastomi
erythroleucu
nigeria
guinea
reveal
previous
undiscov
lasv
strain
identif
new
phylogenet
lineag
rodent
viru
exhibit
persist
asymptomat
infect
due
ubiquit
geograph
distribut
across
west
african
region
populationatrisk
lassa
fever
estim
nearli
million
peopl
lasv
fever
case
typic
result
rodenttohuman
transmiss
event
facilit
contact
infecti
rodent
urin
faec
household
environ
humanvector
interfac
predominantli
occur
resourcelimit
commun
access
health
care
laboratori
diagnost
test
scarc
therefor
thought
mani
potenti
case
infect
never
test
humantohuman
transmiss
viru
observ
often
confin
nosocomi
outbreak
addit
implement
vectorcontrol
strategi
vaccin
key
approach
prevent
control
lassa
fever
outbreak
high
degre
lasv
nucleotid
polymorph
observ
variat
strain
reach
l
genom
segment
respect
lasv
strain
genet
divers
cluster
base
geograph
locat
howev
precis
number
circul
strain
unknown
induct
heterosubtyp
immun
phylogenet
distant
strain
necessari
featur
effect
lassa
fever
vaccin
far
six
distinct
clade
lineag
establish
lineag
iiii
localis
nigeria
lineag
iv
circul
sierra
leon
guinea
liberia
divoir
josiah
strain
lineag
iv
sierra
leon
far
wellstudi
wide
use
model
lasv
infect
design
vaccin
immunogen
emerg
lineag
v
elucid
phylogenet
analysi
strain
mali
divoir
meanwhil
recent
discov
strain
kako
put
classifi
lineag
vi
isol
hylomyscu
pamfi
nigeria
sequenc
data
cluster
import
lasv
infect
index
case
origin
togo
may
reveal
yet
anoth
lineag
evid
support
occurr
viral
reassort
multistrain
infect
within
singl
host
outbreak
lassa
fever
tertiari
hospit
ebonyi
enugu
southeastern
nigeria
phylogenet
analysi
patient
isol
provid
strong
support
role
viru
transmiss
infect
individu
dramat
increas
case
nigerian
lassa
fever
season
launch
investig
possibl
emerg
new
strain
higher
transmiss
rate
two
sequenc
studi
analys
lasv
genom
infect
patient
reveal
high
variabl
deriv
previous
circul
virus
rather
singl
domin
strain
data
indic
phylogenet
cluster
lasv
sampl
collect
similar
time
point
would
expect
event
increas
humantohuman
transmiss
therefor
lassa
viru
transmiss
continu
princip
occur
via
independ
crossspeci
transmiss
event
clear
reason
increas
lassa
fever
case
found
chang
distribut
rodent
reservoir
popul
improv
diseas
diagnosi
surveil
remain
possibl
explan
overal
case
fatal
rate
lasv
infect
high
degre
seropreval
lasvspecif
antibodi
gener
popul
resid
endem
region
indic
infect
mild
asymptomat
result
hospitalis
symptom
lassa
fever
develop
incub
period
day
lassa
fever
initi
present
nonspecif
febril
ill
pose
diagnost
challeng
due
abund
caus
agent
acut
fever
west
africa
vomit
diarrhoea
chest
pain
headach
common
symptom
mild
case
lasv
infect
symptom
subsid
recoveri
typic
commenc
day
diseas
onset
approxim
infect
result
moderatetosever
diseas
case
fatal
rate
approxim
amongst
hospitalis
patient
increas
greater
high
risk
group
includ
pregnant
women
infant
sever
lassa
fever
pregnant
women
result
nearli
mortal
foetus
high
mortal
also
observ
outbreak
nigeria
confirm
case
infect
fatal
sever
case
patient
condit
deterior
day
result
respiratori
distress
pleural
effus
haemorrhag
facial
oedema
increas
vascular
permeabl
consid
indic
poor
diseas
prognosi
seizur
shock
coma
also
document
fatal
due
multiorgan
failur
gener
occur
within
two
week
onset
symptom
histopatholog
examin
tissu
fatal
lassa
fever
case
reveal
hepatocellular
splenic
adrenocort
necrosi
acut
renal
failur
associ
fatal
diseas
moderatetosever
hepat
frequent
observ
lassa
fever
patient
implic
primari
caus
death
level
viremia
highli
predict
diseas
outcom
typic
peak
day
onset
ill
studi
patient
lassa
fever
mortal
risk
patient
present
viremia
median
tissu
cultur
infecti
dose
tcid
ml
time
hospitalis
nearli
four
time
patient
lower
viral
titr
nearli
fatal
case
exhibit
termin
viremia
rang
tcid
ml
survivor
clear
viru
blood
three
week
onset
ill
neurolog
complic
includ
sensorineur
hear
loss
encephalopathi
commonli
observ
lassa
fever
patient
deaf
may
occur
result
mild
sever
ill
estim
effect
case
approxim
half
individu
hear
loss
perman
remaind
partial
restor
hear
take
place
one
three
month
recoveri
potenti
risk
immunemedi
advers
neurolog
effect
key
consider
lassa
fever
vaccin
develop
greater
understand
mechan
lasv
infectionmedi
hear
loss
role
vaccineinduc
immun
respons
phenomenon
requir
advanc
clinic
develop
vaccin
candid
take
place
current
licens
lasv
vaccin
antivir
treatment
lassa
fever
limit
offlabel
use
ribavirin
report
reduc
risk
mortal
administ
within
first
six
day
ill
earli
studi
benefit
dramat
diminish
drug
start
later
cours
diseas
howev
investig
efficaci
ribavirin
requir
limit
recent
evid
support
find
end
two
ongo
clinic
trial
studi
effect
intraven
administr
ribavirin
patient
probabl
suspect
case
lassa
fever
crimean
congo
haemorrhag
fever
lasv
exhibit
broad
tissu
tropism
infect
liver
spleen
adren
gland
organ
viru
primarili
target
myeloid
lineag
cell
antigenpres
cell
apc
dendrit
cell
dc
macrophag
cell
type
support
high
level
viral
replic
lasv
infect
antagon
activ
matur
apc
result
impair
antigen
process
present
despit
fact
infect
apc
migrat
drain
lymph
node
matur
remain
imped
throughout
cours
lasv
infect
caus
dysregul
adapt
immun
respons
reduc
viral
clearanc
complet
disrupt
function
apc
lasv
may
correl
lack
adapt
immun
respons
observ
fatal
case
present
lasv
antigen
immatur
dc
may
lead
immun
toler
ultim
immunosuppress
mopeia
viru
mopv
highli
similar
nonpathogen
arenaviru
also
infect
replic
dc
macrophag
high
level
howev
cell
strongli
activ
mopv
infect
increas
express
type
ifn
observ
indic
high
level
apc
activ
characteris
protect
immun
respons
wherea
impair
activ
cell
case
lasv
infect
determin
featur
pathogenesi
type
ifn
respons
shown
play
critic
role
control
infect
earli
stage
suppress
viral
replic
contribut
activ
virusspecif
adapt
immun
respons
mice
defici
type
ifn
receptor
succumb
lethal
infect
addit
cytokin
respons
nonhuman
primat
nhp
surviv
lasv
infect
indic
strong
transient
upregul
earli
stage
infect
convers
upregul
express
nonsurvivor
observ
late
time
point
antibodi
respons
remain
low
clinic
diseas
increas
long
recoveri
gener
thought
resolut
lasv
infect
princip
mediat
cellular
immun
assert
support
experiment
observ
lassa
fever
nhp
transient
strong
activ
prolifer
cell
observ
day
postinfect
anim
effect
control
infect
contrast
tcell
respons
undetect
anim
develop
fatal
diseas
base
express
tcell
activ
marker
prolifer
marker
nhp
model
lassa
fever
sever
diseas
associ
tcell
deplet
secondari
lymphoid
tissu
transient
lymphopenia
decreas
tcell
prolifer
uncontrol
viru
replic
human
lasvspecif
cell
activ
earli
infect
continu
detect
recoveri
despit
low
absent
antibodi
respons
memori
tcell
respons
lasv
gpc
np
persist
sever
year
initi
infect
earli
lassa
fever
vaccin
develop
approach
base
inactiv
whole
viru
protect
rhesu
macaqu
lethal
challeng
despit
detect
antibodi
respons
lasv
gpc
np
immunis
find
impli
crucial
role
cellmedi
respons
resolv
lasv
infect
liveattenu
viral
vectorbas
vaccin
express
lasv
gp
andor
np
antigen
favor
potent
induc
tcell
respons
lasv
antigenspecif
cell
detect
vaccin
liveattenu
mopvlasv
reassort
clone
vesicularstomat
viru
base
vaccin
alphaviru
replicon
particl
vaccin
anim
model
infect
lasvinfect
individu
produc
igm
igg
antibodi
howev
antibodi
produc
rel
low
level
earli
infect
neutralis
gener
antibodi
product
lasv
infect
correl
diseas
outcom
neutralis
antibodi
detect
month
resolut
acut
infect
titr
initi
low
neutralis
antibodi
titr
continu
rise
month
convalesc
perhap
due
low
level
persist
viru
continu
stimul
b
cell
seroconvert
individu
antibodi
primarili
specif
gp
np
structur
studi
bcell
antigen
epitop
identifi
two
bind
site
six
site
four
site
np
structur
glycan
shield
lasv
gp
implic
barrier
induct
neutralis
antibodi
infect
thu
potenti
limit
role
bcell
respons
protect
howev
signific
humor
respons
protect
may
underst
administr
human
monoclon
antibodi
therapi
guinea
pig
nhp
model
lassa
fever
shown
protect
sever
diseas
monoclon
antibodi
use
studi
high
neutralis
index
potenti
suggest
strong
neutralis
respons
may
protect
even
though
neutralis
antibodi
extens
produc
natur
infect
final
recent
studi
inactiv
lasv
rabi
viru
vaccin
provid
evid
role
nonneutralis
antibodi
viru
clearanc
via
antibodydepend
cellular
cytotox
antibodydepend
cellular
phagocytosi
vitro
model
infect
therefor
vaccin
capabl
induc
high
titr
antibodi
may
achiev
protect
despit
fact
antibodi
play
lesser
role
natur
acquir
immun
given
annual
incid
lassa
fever
vaccin
licensur
like
proceed
via
tradit
approv
pathway
multisit
efficaci
trial
west
africa
rather
us
food
drug
administr
anim
rule
moreov
molecular
pathogenesi
lasv
infect
immun
correl
protect
fulli
understood
valu
anim
model
predict
clinic
outcom
vaccin
may
limit
reason
effici
progress
promis
vaccin
candid
clinic
trial
evalu
crucial
accur
characteris
vaccinemedi
immun
nevertheless
welldefin
anim
model
recapitul
element
human
lasv
infect
critic
import
compil
vaccin
immunogen
efficaci
data
inform
futur
clinic
trial
anim
model
also
use
studi
vaccineinduc
heterosubtyp
immun
challeng
experi
use
heterolog
strain
lasv
would
provid
clearest
inform
crossprotect
efficaci
howev
repres
reliabl
lethal
model
infect
wide
establish
mani
differ
lasv
strain
almost
vaccin
efficaci
studi
perform
wildtyp
speciesadapt
josiah
strain
lasv
lineag
iv
import
area
futur
research
develop
suscept
rodent
nhp
model
lasv
infect
epidemiolog
relev
strain
particularli
current
circul
nigeria
feasibl
approach
collect
preliminari
evid
heterosubtyp
immun
conduct
antibodi
tcell
crossreact
assay
purifi
antigen
peptid
cocktail
synthesis
differ
strain
may
use
detect
crossreact
antibodi
tcell
respons
vitro
assay
elisa
elispot
notabl
approach
use
assess
crossreact
respons
divers
lasv
strain
human
sampl
obtain
futur
clinic
trial
mani
differ
rodent
nhp
speci
explor
model
lassa
fever
thorough
discuss
lassa
fever
anim
model
investig
outsid
scope
review
instead
focu
wide
adopt
model
preclin
efficaci
studi
rodentborn
viru
immun
respons
lasv
infect
differ
rodent
nhpshuman
nevertheless
certain
featur
lassa
fever
clinic
diseas
immunobiolog
reproduc
rodent
specif
rodent
model
wide
use
studi
vaccinemedi
respons
earli
stage
preclin
develop
howev
potenti
limit
scope
model
accur
predict
vaccin
outcom
nhp
human
acknowledg
mous
model
offer
econom
approach
studi
vaccin
immunogen
obtain
initi
efficaci
data
pathogen
lasv
infect
mice
highli
depend
upon
host
strain
age
rout
infect
fulli
immun
compet
mous
strain
lasv
infect
rare
lethal
particularli
use
peripher
rout
inocul
antivir
test
studi
diseas
pathogenesi
reli
immun
knock
strain
ko
develop
fatal
infect
optim
suit
studi
immun
respons
vaccin
howev
intracrani
inocul
young
adult
inbr
cbaj
mice
dose
ld
shown
result
fatal
convuls
immunopatholog
diseas
resembl
lymphochoriomenig
viru
lcmv
infect
recent
studi
util
cbaj
mous
model
evalu
tcell
respons
multipl
vaccin
candid
assess
role
protect
recent
report
geovax
lab
inc
announc
result
efficaci
test
lassa
fever
vaccin
base
modifi
vaccinia
viral
ankara
viruslik
particl
platform
mous
model
infect
singl
dose
confer
protect
lethal
lasv
challeng
howev
studi
yet
publish
peerreview
literatur
mous
model
use
specifi
inbr
strain
outbr
hartley
guinea
pig
wide
adopt
small
anim
model
studi
lassa
fever
test
vaccin
candid
pathogen
differ
base
host
strain
viru
strain
intraperiton
infect
josiah
strain
lasv
produc
uniformli
lethal
diseas
inbr
strain
guinea
pig
characteris
fever
weight
loss
death
within
two
week
lymphopenia
neutrophilia
reduc
level
serum
albumin
also
observ
viraemia
first
detect
four
day
infect
peak
day
infect
high
viral
titr
found
lymph
node
salivari
gland
spleen
pancrea
lung
viral
replic
also
detect
liver
heart
brain
kidney
adren
gland
lasv
infect
guinea
pig
may
myocardiotrop
less
hepatotrop
human
hartley
guinea
pig
lethal
josiah
strain
lasv
infect
vari
viral
titr
lower
hartley
guinea
pig
viral
replic
limit
comparison
inbr
anim
recent
lethal
model
lassa
fever
outbr
hartley
guinea
pig
develop
four
passag
josiah
strain
lasv
host
strain
intraperiton
inocul
lasv
anim
uniformli
succumb
diseas
day
postinfect
clinic
manifest
lasv
infect
resembl
observ
inbr
guinea
pig
model
new
lethal
hartley
guinea
pig
model
current
appli
vaccin
efficaci
studi
far
follow
lasv
strain
test
inbr
strain
guinea
pig
challeng
model
nigeria
lineag
iii
josiah
sierra
leon
lineag
iv
nigeria
lineag
ii
liberia
lineag
iv
sorombar
mali
lineag
v
pinneo
nigeria
lineag
josiah
infect
lethal
anim
within
day
postinfect
sorombar
pinneo
infect
uniformli
lethal
inbr
guinea
pig
model
anim
exhibit
sign
diseas
ie
lethargi
weight
loss
day
postinfect
anim
subsequ
recov
other
succumb
diseas
infecti
viru
challeng
nhp
consid
close
replic
human
lassa
fever
lassa
fever
rhesu
cynomolgu
macaqu
extens
studi
howev
marmoset
challeng
model
appli
vaccin
efficaci
studi
recent
experiment
observ
josiah
strain
lasv
infect
rhesu
macaqu
suggest
viraemia
appear
day
postinfect
continu
increas
anim
succumb
diseas
gross
patholog
chang
includ
petechia
mildtomoder
pleural
effus
observ
anim
viru
detect
mani
organ
name
adren
gland
spleen
liver
kidney
heart
lung
intestin
pancrea
bone
marrow
lymph
node
thymu
skelet
muscl
salivari
gland
ovari
bladder
brain
cerebrospin
fluid
ocular
fluid
typic
largest
quantiti
viru
found
spleen
liver
adren
bone
marrow
intestin
similar
human
lassa
fever
sever
patholog
observ
hepat
renal
splenic
tissu
howev
meningoenceph
system
pulmonari
vascul
skelet
muscl
myositi
pronounc
rhesu
macaqu
model
human
lassa
fever
clinic
manifest
josiah
strain
lasv
infect
cynomolgu
macaqu
includ
fever
weight
loss
depress
acut
respiratori
syndrom
clinic
featur
includ
thrombocytopenia
lymphopenia
enlarg
spleen
lymph
node
well
patholog
alter
liver
lung
endothelium
manifest
close
align
observ
human
viraemia
detect
day
infect
increas
death
high
level
viraemia
elev
liver
enzym
low
level
proinflammatori
cytokin
depress
tcell
activ
predictor
poor
diseas
outcom
mark
patholog
liver
infect
anim
high
product
correl
lethal
outcom
also
observ
human
presenc
multifoc
sever
central
nervou
system
lesion
addit
characterist
termin
ill
cynomolgu
macaqu
common
marmoset
infect
josiah
strain
lasv
develop
system
diseas
close
resembl
clinic
patholog
featur
fatal
diseas
macaqu
human
major
symptom
includ
fever
weight
loss
high
viraemia
viral
rna
load
tissu
elev
liver
enzym
termin
ill
day
histopatholog
examin
reveal
multifoc
hepat
adren
necrosi
interstiti
nephriti
lymphoid
deplet
small
size
marmoset
rel
macaqu
may
provid
way
reduc
cost
associ
nhp
efficaci
studi
increas
eas
handl
experiment
pauciti
studi
infect
nhp
lasv
strain
divers
lineag
addit
josiah
strain
lasv
strain
use
heterolog
challeng
experi
involv
cynomolgu
macaqu
result
uniformli
lethal
diseas
day
postinfect
signific
progress
achiev
preclin
develop
lassa
fever
vaccin
numer
candid
demonstr
efficaci
anim
model
infect
first
phase
trial
evalu
safeti
immunogen
lassa
fever
vaccin
candid
schedul
begin
shortli
target
product
profil
tpp
lassa
viru
vaccin
provid
guidelin
futur
compar
assess
vaccin
deploy
nonemerg
set
tpp
list
set
minimum
prefer
vaccin
requir
prevent
lassa
fever
among
atrisk
group
includ
healthcar
worker
commun
endem
area
accept
vaccin
least
suitabl
use
healthi
adult
children
prefer
also
safe
infant
pregnant
women
mild
transient
advers
effect
relat
immunis
toler
addit
data
indic
vaccin
induc
neurolog
complic
associ
lassa
fever
includ
sensorineur
hear
loss
neuropsychiatr
side
effect
advantag
demonstr
least
prefer
protect
efficaci
infect
diseas
clinic
trial
requir
howev
trial
measur
clinic
efficaci
feasibl
anim
efficaci
data
alongsid
clinic
immunogen
data
may
consid
instead
singledos
regimen
ideal
threedos
confer
protect
lasv
lineag
ieiv
minimum
three
prefer
five
year
may
deem
accept
longer
term
protect
maintain
booster
vaccin
final
vaccin
must
minimum
shelf
life
month
six
month
howev
optim
candid
would
possess
shelf
life
least
five
year
thermost
higher
temperatur
although
clinic
assess
lasv
vaccin
candid
provid
true
test
align
tpp
earli
indic
may
gather
preclin
studi
exist
clinic
data
vaccin
platform
previous
appli
infecti
target
worth
note
current
tpp
focus
requir
vaccin
prevent
use
nonemerg
settingrath
outbreak
scenarioto
address
burden
lassa
fever
endem
countri
desir
profil
outbreak
vaccin
may
differ
follow
section
review
major
platform
employ
past
present
lassa
fever
vaccin
develop
effort
data
vaccin
candid
discuss
brief
also
summaris
tabl
detail
intext
discuss
provid
candid
believ
like
progress
clinic
trial
potenti
futur
licensur
mopvlasv
reassort
clone
five
vaccin
endors
coalit
epidem
prepared
innov
cepi
acceler
preclin
earli
clinic
develop
cepi
http
cepinet
rel
new
allianc
form
support
financ
vaccin
develop
prevent
infecti
diseas
epidem
lassa
fever
list
prioriti
pathogen
past
year
cepi
award
contract
five
vaccin
candid
base
dna
recombin
viru
platform
technolog
platformbas
vaccin
pois
expedit
progress
clinic
evalu
due
establish
safeti
profil
vaccin
platform
alreadi
use
produc
signific
quantiti
clinicalgrad
product
abil
manufactur
vaccin
scale
establish
summaris
data
guinea
pig
nhp
efficaci
studi
aforement
vaccin
modal
avail
clinic
safeti
immunogen
nonlassa
vaccin
individu
platform
also
discuss
use
liveattenu
viru
recombin
viral
vector
attract
approach
lassa
fever
vaccin
develop
epidemiolog
observ
lassa
fever
west
africa
suggest
surviv
singl
lasv
infect
may
confer
long
term
protect
fatal
diseas
reinfect
differ
strain
boost
tabl
addit
efficaci
data
lassa
fever
vaccin
guinea
pig
nhp
model
infect
immun
although
estim
lassa
fever
case
experi
reinfect
annual
recurr
clinic
diseas
never
document
cellular
immun
respons
implic
major
role
resolv
lasv
infect
live
vaccin
provid
effect
natur
pathway
present
antigen
mhc
molecul
moreov
given
potenc
live
vaccin
like
meet
tpp
recommend
confer
protect
one
dose
multipl
replicationcompet
vaccinia
virusvector
candid
encod
lasv
antigen
featur
tabl
achiev
variabl
efficaci
guinea
pig
macaqu
model
lassa
fever
vaccinialist
encod
np
strain
lineag
iii
protect
vaccin
outbr
hartley
guinea
pig
challeng
strain
lasv
vaccinianybhvector
vaccin
encod
josiah
strain
lasv
np
confer
protect
homolog
viru
challeng
inbr
strain
guinea
pig
meanwhil
studi
vaccinianybh
encod
josiah
strain
lasv
gpc
protect
immunis
guinea
pig
howev
vaccinianybhgpc
evalu
homolog
challeng
experi
rhesu
macaqu
protect
efficaci
observ
studi
first
indic
guinea
pig
model
infect
may
entir
predict
respons
nhp
studi
compar
vaccinianybh
vaccin
inbr
strain
guinea
pig
express
differ
region
josiah
strain
lasv
gpc
np
reveal
full
length
gpc
includ
subunit
necessari
protect
lasv
challeng
followup
investig
rhesu
cynomolgu
macaqu
indic
vaccin
gpc
np
antigen
provid
modest
increas
versu
protect
compar
vaccin
gpc
alon
despit
promis
result
deploy
replicationcompet
vacciniabas
vaccin
popul
pose
signific
safeti
concern
therefor
lasv
vaccin
base
platform
unlik
licens
use
africa
yellow
fever
viru
platform
use
construct
chimer
virus
express
antigen
varieti
pathogen
includ
lasv
gp
excel
safeti
efficaci
record
use
vector
japanes
enceph
dengu
viru
west
nile
viru
vaccin
undergo
test
phase
ii
iii
clinic
trial
gpc
lasv
strain
av
insert
e
gene
recombin
viru
replicationcompet
deepli
attenu
induc
immun
respons
pathogen
vaccin
protect
inbr
strain
guinea
pig
lethal
challeng
josiah
strain
lasv
howev
product
recombin
viru
hinder
instabl
result
insert
fulllength
gpc
site
recombin
success
passag
reduc
transgen
size
subunit
lasv
gpc
separ
distinct
vector
combin
vaccin
protect
inbr
strain
guinea
pig
fatal
homolog
lasv
challeng
subsequ
efficaci
primeboost
vaccin
assess
marmoset
lethal
challeng
josiah
strain
lasv
immunis
regimen
protect
vaccin
anim
die
clinic
sign
lassa
fever
lukashevich
unpublish
data
review
data
support
assert
respons
immunis
guinea
pig
model
infect
may
fulli
predict
nhp
elucid
caus
low
vaccin
immunogen
necessari
consid
tenabl
option
control
lassa
fever
yellow
fever
coendem
area
africa
replicationdefect
alphaviru
replicon
particl
platform
deliv
transduc
encod
antigen
carri
singl
infect
cycl
thu
maintain
prefer
safeti
profil
kill
vaccin
possess
greater
immunogen
immunogen
studi
rna
replicon
deriv
venezuelan
equin
enceph
viru
veev
show
vector
serv
adjuv
promot
cell
respons
deliv
antigen
particularli
attract
featur
lasv
vaccin
design
veev
rna
replicon
express
either
gpc
np
josiah
strain
lasv
fulli
protect
inbr
strain
guinea
pig
lethal
infect
josiah
strain
lasv
howev
three
dose
veev
requir
achiev
protect
meet
minimum
requir
tpp
would
far
difficult
deploy
lasvendem
region
rural
limit
infrastructur
singledos
vaccin
howev
multidos
immunis
regimen
may
feasibl
administ
certain
group
healthcar
profession
militari
personnel
would
access
followup
design
interv
recent
multival
veev
vaccin
encod
lasv
gpc
lasv
vlpv
distantli
relat
strain
lp
lineag
josiah
lineag
iv
develop
lasv
vlpv
protect
inbr
cbaj
mice
upregul
dendrit
cell
implic
play
major
role
crosspresent
vaccin
result
induct
crossreact
multifunct
tcell
respons
stimul
immun
splenocyt
peptid
cocktail
deriv
lasv
lineag
ieiv
reassort
vaccin
platform
mopvlasv
clone
design
retain
nonpathogen
profil
mopv
keep
desir
induct
strong
protect
immunolog
respons
lasv
clone
genotyp
characterist
lsegment
rna
mopv
strain
ssegment
rna
lasv
josiah
strain
singl
subcutan
inject
pfu
fulli
protect
inbr
strain
guinea
pig
lethal
challeng
ld
josiah
strain
lasv
n
heterolog
challeng
strain
lasv
lineag
ii
n
deliv
via
subcutan
inocul
day
postimmunis
vaccin
anim
express
clinic
manifest
diseas
biochem
abnorm
observ
period
day
histolog
examin
reveal
lesion
tissu
anim
challeng
lasv
viraemia
detect
vaccin
guinea
pig
day
challeng
suggest
induc
steril
immun
nonneutralis
igg
antibodi
lasv
predominantli
antinp
detect
end
first
week
vaccin
peak
shortli
challeng
found
safe
immunogen
efficaci
marmoset
vaccin
associ
increas
cell
subcutan
vaccin
pfu
protect
marmoset
n
lethal
challeng
josiah
strain
lasv
pfu
also
deliv
subcutan
vaccin
anim
surviv
studi
endpoint
dpi
develop
clinic
sign
infect
wherea
control
anim
succumb
diseas
one
marmoset
develop
transient
viraemia
lasv
detect
blood
tissu
vaccin
anim
challeng
test
anim
model
replic
deepli
attenu
induc
viremia
biochem
clinic
abnorm
detail
examin
two
rhesu
macaqu
infect
mopvla
reassort
reveal
histolog
lesion
diseas
sign
respons
safeti
concern
use
popul
rhesu
macaqu
advanc
stage
simian
immunodefici
viru
infect
vaccin
macaqu
display
clinic
sign
arenaviru
diseas
develop
chronic
infect
vaccin
anim
develop
cellular
humor
immun
respons
despit
demonstr
advantag
platform
carri
risk
classif
vector
viru
wildtyp
mopv
mopv
classifi
risk
group
eu
biosafeti
regul
risk
group
us
cdc
pose
signific
obstacl
develop
vaccin
inovio
pharmaceut
dna
vaccin
encod
lasv
josiah
strain
gpc
gene
plasvgpc
codonoptimis
enhanc
express
recipi
speci
ie
guinea
pig
macaqu
strain
guinea
pig
n
vaccin
three
time
via
dermal
electropor
vaccin
threeweek
interv
fulli
protect
intramuscular
challeng
lethal
dose
josiah
strain
lasv
pfu
vaccin
guinea
pig
remain
afebril
sign
ill
display
viremia
studi
endpoint
day
postinfect
contrast
guinea
pig
receiv
mockvaccin
n
empti
plasmid
vaccin
n
develop
fever
display
sign
ill
lost
weight
succumb
diseas
day
postinfect
dpi
neutralis
antibodi
titr
increas
vaccin
anim
peak
around
day
postinfect
decreas
gradual
end
studi
subset
plasvgpcvaccin
strain
guinea
pig
n
rechalleng
pfu
josiah
strain
lasv
day
endpoint
initi
studi
alongsid
control
anim
n
monitor
weight
bodi
temperatur
symptom
develop
day
postreinfect
vaccin
anim
surviv
studi
endpoint
never
develop
sign
diseas
compar
control
anim
febril
succumb
diseas
dpi
subsequ
efficaci
threedos
twodos
vaccin
regimen
establish
nhp
model
cynomolgu
macaqu
n
receiv
two
three
mg
dose
plasvgpc
administ
partial
dose
mg
four
differ
site
via
dermal
electropor
fourweek
interv
electropor
plasvgpc
induc
modest
level
neutralis
antibodi
nhp
expos
pfu
josiah
strain
lasv
five
week
final
vaccin
monitor
day
symptom
ill
fever
sustain
viremia
detect
vaccin
anim
challeng
mockvaccin
nhp
succumb
diseas
dpi
remaind
becam
critic
ill
persist
studi
endpoint
albeit
chronic
neurolog
deficit
advancedstag
lassa
fever
vaccin
candid
first
administ
human
phase
trial
soon
begin
recruit
healthi
adult
volunt
evalu
safeti
toler
immunogen
candid
bear
addit
advantag
rel
eas
speed
manufactur
comparison
recombin
viral
vector
platform
despit
advantag
dna
vaccin
exhibit
low
immunogen
requir
multipl
dose
deliv
via
dermal
electropor
order
enhanc
vaccin
potenc
achiev
full
protect
widespread
adopt
dna
electropor
devic
multidos
immunis
regimen
challeng
implement
rural
region
west
africa
lassa
fever
endem
particularli
outbreak
howev
case
veevvector
lasv
vaccin
multidos
electroporationdeliv
dna
vaccin
may
administr
localis
group
prioriti
vaccine
ie
hospitalclin
employe
two
contract
award
cepi
acceler
develop
candid
util
recombin
vesicular
stomat
viru
vsv
platform
express
lasv
gpc
josiah
strain
intern
aid
vaccin
initi
candid
develop
profectu
bioscienc
emerg
biosolut
use
vesiculovax
vector
vsv
negativesens
singlestrand
rna
viru
rhabdovirida
famili
use
express
antigen
varieti
pathogen
vsv
platform
replic
compet
clinic
trial
provid
evid
safeti
immunogen
attenu
recombin
vsv
vector
human
perhap
notabl
follow
ebov
diseas
outbreak
west
africa
vsv
vaccin
express
ebov
gpc
demonstr
efficaci
ring
vaccin
trial
protect
determin
primarili
antibodymedi
last
month
nhp
model
infect
perceiv
advantag
use
vsv
system
high
level
immunogen
fact
littl
preexist
immun
vector
might
limit
vaccin
potenc
limit
platform
includ
absenc
thermost
formula
necessit
unbroken
coldchain
transport
storag
second
despit
replic
high
titr
sever
cell
line
negativesens
rna
viru
rescu
recombin
vsv
plasmid
dna
cumbersomerequir
cotransfect
five
plasmid
permiss
cell
line
final
reactogen
vsvvector
vaccin
may
pose
concern
phase
trial
high
incid
fever
headach
chill
fatigu
myalgia
observ
immunis
first
studi
character
vsvbase
lassa
fever
vaccin
cynomolgu
macaqu
n
vaccin
intramuscularli
singl
dose
pfu
challeng
intramuscularli
four
week
later
lethal
dose
pfu
josiah
strain
lasv
time
challeng
moderateor
highlevel
igg
lowlevel
neutralis
antibodi
titr
lasv
detect
vaccin
anim
nhp
vaccin
fulli
protect
clinic
sign
diseas
nhp
receiv
control
vaccin
n
began
show
sign
ill
day
anim
succumb
diseas
dpi
day
nhp
virem
anim
clear
viru
day
wherea
control
nhp
maintain
high
viremia
euthanasia
given
signific
genet
variat
strain
studi
test
whether
induc
crossprotect
immun
geograph
distinct
lasv
isol
strain
guinea
pig
n
per
group
receiv
intraperiton
vaccin
pfu
challeng
four
week
later
tcid
lasv
strain
sierra
leon
josiah
lineag
iv
liberia
lineag
iv
mali
sorombar
lineag
v
nigeria
pinneo
lineag
josiah
infect
lethal
control
vaccin
anim
within
day
postchalleng
guinea
pig
vaccin
show
sign
ill
throughout
experi
infecti
lasv
could
isol
tissu
sampl
collect
plan
necropsi
dpi
sorombar
pinneo
infect
fulli
lethal
guinea
pig
model
howev
control
vaccin
anim
exhibit
sign
diseas
lethargi
weight
loss
around
dpi
guinea
pig
progress
termin
ill
wherea
other
persist
recov
day
contrast
guinea
pig
fulli
resist
challeng
display
sign
diseas
studi
cynomolgu
macaqu
n
vaccin
intramuscularli
singl
dose
pfu
control
vaccin
four
week
later
nhp
challeng
intramuscularli
tcid
liberian
isol
dpi
control
nhp
exhibit
symptom
diseas
progress
termin
ill
day
nhp
display
sign
infect
lasv
detect
blood
sampl
sequenc
data
suggest
lasv
strain
lineag
ii
iii
circul
ongo
nigerian
outbreak
yet
test
efficaci
isol
nevertheless
data
support
feasibl
effect
protect
multipl
lasv
lineag
singl
vaccin
profectu
bioscienc
vesiculovax
platform
develop
improv
safeti
vsv
vector
attenu
vector
contain
transloc
n
gene
truncat
cytoplasm
tail
immunogen
vaccin
demonstr
cynomolgu
macaqu
mild
inflammatori
respons
associ
intrathalam
inocul
attenu
vector
use
gener
vaccin
ebov
marburg
viru
protect
nhp
data
vesiculovax
vector
lassa
fever
vaccin
yet
publish
themi
bioscienc
partnership
institut
pasteur
develop
replicationcompet
liveattenu
schwarz
strain
measl
viru
vector
express
lasv
gpc
np
larg
insert
capac
vector
enabl
stabl
insert
antigen
singl
dose
vaccin
mvlasvnp
gpc
protect
macaqu
lethal
lasv
challeng
mateo
manuscript
submit
review
although
yet
demonstr
vaccin
express
lasv
gp
np
antigen
may
induc
broad
crossreact
larg
pool
memori
cell
phylogenet
group
lasv
thelper
cell
epitop
lasvexpos
individu
carri
sequenc
highli
conserv
sequenc
arenavirus
howev
approach
may
pose
practic
challeng
mani
diagnost
test
lassa
fever
base
detect
npspecif
respons
np
also
includ
vaccin
would
clear
diagnost
marker
distinguish
vaccin
infect
lasv
safeti
immunogen
measl
vector
platform
establish
human
clinic
trial
themi
bioscienc
mvchik
vaccin
protect
chikungunya
viru
infect
randomisedcontrol
phase
trial
enrol
healthi
volunt
age
year
receiv
mvchik
n
measl
prime
vaccin
mvchik
n
control
vaccin
n
mvchik
deliv
intramuscularli
tcid
two
differ
administr
regimen
primari
endpoint
immunogen
defin
presenc
neutralis
antibodi
chikungunya
viru
virusspecif
neutralis
antibodi
detect
mvchikvaccin
group
one
two
dose
seriou
advers
event
relat
vaccin
report
overal
found
safe
well
toler
highli
immunogen
healthi
adult
moreov
preexist
immun
measl
vector
affect
vaccin
immunogen
data
support
broader
use
platform
emerg
pathogen
lassa
fever
recombin
adenovirus
use
gene
therapi
vaccin
vector
decad
howev
widespread
presenc
preexist
neutralis
antibodi
common
serotyp
human
adenovirus
preclud
immunogen
protect
efficaci
clinic
trial
inhibit
vectormedi
deliveri
antigen
adopt
simian
adenovir
vector
human
popul
less
expos
circumv
problem
antivector
immun
vector
deriv
chimpanze
adenoviru
bear
advantag
replic
incompet
due
delet
singl
transcript
unit
reduc
risk
advers
effect
administ
human
addit
delet
unit
enabl
insert
transgen
kb
size
like
chad
vector
achiev
persist
highlevel
express
divers
antigen
modif
region
substitut
open
read
frame
human
optimis
replic
rate
yield
human
cell
line
despit
lack
adenovir
replic
immunis
demonstr
protect
efficaci
outbr
hartley
guinea
pig
model
lethal
josiah
strain
lasv
infect
one
dose
gpspecif
igg
antibodi
detect
vaccin
boost
administr
second
vaccin
dose
addit
immunogen
experi
outbr
mice
provid
evid
induct
crossreact
tcell
respons
gp
lasv
lineag
iiii
manuscript
prepar
applic
platform
divers
rang
emerg
pathogen
support
multipl
studi
demonstr
singl
dose
vaccin
fulli
protect
inbr
balbc
mice
sheep
goat
cattl
lethal
rift
valley
fever
protect
transgen
human
dipeptidyl
mice
lethal
middl
east
respiratori
syndrom
offer
inbr
balbc
mice
sterilis
protect
zika
viru
infect
vaccin
candid
potent
induc
antigenspecif
tcell
respons
high
titr
neutralis
antibodi
safeti
evalu
human
complet
influenza
np
younger
older
adult
phase
randomisedcontrol
trial
individu
age
year
individu
age
year
younger
adult
receiv
one
four
heterolog
primeboost
immunis
regimen
np
mvanp
mi
given
eight
week
apart
n
np
mvanp
mi
given
week
apart
n
mvanp
np
given
eight
week
apart
n
mvanp
np
given
week
apart
n
older
adult
receiv
either
np
alon
n
np
mvanp
administ
eight
week
apart
n
subject
monitor
month
record
advers
effect
measur
tcell
respons
np
found
safe
well
toler
seriou
vaccinerel
advers
effect
record
lower
proport
older
adult
experienc
advers
effect
younger
adult
immunis
regimen
found
boost
preexist
level
cell
age
greater
amplif
observ
heterolog
primeboost
vaccin
primeonli
vaccin
safe
administr
chad
vector
document
children
phase
trial
safeti
immunogen
heterolog
primeboost
vaccin
modifi
vaccinia
viru
ankara
mva
express
multipl
epitop
thrombospondin
adhes
protein
metrap
malaria
antigen
assess
malariaexpos
children
infant
gambia
burkina
faso
children
n
enrol
accord
follow
age
group
year
gambia
month
old
burkina
faso
month
old
gambia
week
old
gambia
within
group
multipl
combin
low
high
dose
viral
vector
test
vaccin
well
toler
four
cohort
children
advers
effect
mild
intens
dose
depend
resolv
quickli
primeboost
immunis
regimen
found
highli
immunogen
young
children
highest
level
antigenspecif
cell
measur
old
infant
control
infecti
diseas
outbreak
vaccin
requir
vaccin
stockpil
atrisk
region
often
resourcelimit
possess
low
variabl
coldchain
capac
abil
vaccin
thermostabilis
extend
period
time
without
signific
loss
potenc
make
applic
platform
toward
emerg
pathogen
vaccin
develop
especi
advantag
rift
valley
fever
vaccin
encod
viral
envelop
glycoprotein
gn
gc
thermostabilis
via
desicc
glass
fibr
membran
trehalos
sucros
sugar
store
month
immunogen
vaccin
determin
measur
neutralis
antibodi
titr
immunis
cattl
comparison
elicit
standard
coldchain
vaccin
anim
vaccin
thermostabilis
store
month
mount
function
antibodi
respons
compar
receiv
coldchain
vaccin
dose
titr
within
rang
associ
protect
rvf
cattl
despit
advantag
discuss
platform
still
earli
stage
develop
although
efficaci
demonstr
anim
model
vaccin
yet
complet
efficaci
assess
human
extend
durabl
vaccinemedi
immun
respons
yet
evalu
furthermor
vaccin
develop
multipl
coendem
infect
includ
lassa
fever
ebola
viru
diseas
plasmodium
falciparum
malaria
risk
reduc
vaccin
efficaci
due
antivector
immun
result
previou
vaccin
investig
care
consider
challeng
studi
requir
vaccin
candid
progress
licensur
deploy
may
use
nonemerg
outbreak
set
expect
effect
singl
dose
lassa
fever
one
mani
diseas
concentr
lowand
middleincom
countri
urgent
need
licens
vaccin
augment
support
entiti
like
cepi
like
multipl
lassa
fever
vaccin
candid
reach
clinic
trial
within
next
year
order
feasibl
develop
test
manufactur
distribut
vaccin
diseas
new
strategi
reduc
develop
cost
must
identifi
use
platform
like
dna
vsv
mv
establish
safeti
immunogen
profil
human
help
acceler
earli
stage
clinic
develop
decreas
manufactur
cost
wherea
opportun
test
efficaci
novel
vaccin
ebola
number
case
lassa
fever
west
africa
allow
multipl
clinic
efficaci
trial
may
lead
licensur
deploy
one
candid
vaccin
previous
state
clinic
evalu
promis
vaccin
candid
must
identifi
base
align
tpp
import
monitor
current
situat
nigeria
continu
effort
characteris
circul
virus
elucid
caus
rapid
increas
case
need
studi
vector
popul
geograph
distribut
may
also
order
final
import
test
crossprotect
efficaci
preclin
vaccin
candid
lineag
ii
iii
isol
current
circul
nigerian
outbreak
prepar
lassa
fever
vaccin
move
toward
clinic
studi
necessari
bolster
local
diagnost
capabl
wellvalid
assay
especi
pointofcar
fieldbas
technolog
improv
diagnost
tool
requir
detect
capabl
span
rang
lasv
polymorph
multiplex
assay
distinguish
lassa
fever
acut
febril
ill
preval
region
